Literature DB >> 6594185

Hepatic dysfunction and jaundice following high-dose cytosine arabinoside.

C B George, R P Mansour, J Redmond, D R Gandara.   

Abstract

Two patients with poor-prognosis leukemia were treated with high-dose cytosine arabinoside (Ara-C), 3 g/m2, for induction. Both patients developed serious jaundice in the second posttreatment week. Clinically, the jaundice was characterized by conjugated hyperbilirubinemia, normal amino transferase levels, significant elevation of alkaline phosphatase, and no evidence of obstruction. Microscopic examination of the liver showed only passive congestion with blood, and no bile lakes or plugs. This was believed to be most consistent with drug-induced intrahepatic cholestasis, possibly as a result of injury to the hepatocyte transport system.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6594185     DOI: 10.1002/1097-0142(19841201)54:11<2360::aid-cncr2820541109>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Jaundice and hepatorenal syndrome associated with cytosine arabinoside.

Authors:  D W Kirtley; M L Votaw; E Thomas
Journal:  J Natl Med Assoc       Date:  1990-03       Impact factor: 1.798

2.  Acute Hepatotoxicity After High-Dose Cytarabine for the Treatment of Relapsed Acute Myeloid Leukemia: A Case Report.

Authors:  Samuel H Fu; Alexander H Flannery; Melissa L Thompson Bastin
Journal:  Hosp Pharm       Date:  2018-06-01

Review 3.  The toxicity of cytarabine.

Authors:  J Stentoft
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

Review 4.  Drug-induced cholestasis.

Authors:  H J Zimmerman; J H Lewis
Journal:  Med Toxicol       Date:  1987 Mar-Apr

5.  Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.

Authors:  J H Marsh; W Kreis; B Barile; S Akerman; P Schulman; S L Allen; L C DeMarco; M W Schuster; D R Budman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study.

Authors:  Daniel Shepshelovich; Yonatan Edel; Hadar Goldvaser; Tal Dujovny; Ofir Wolach; Pia Raanani
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.